{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T19:37:45Z","timestamp":1788550665860,"version":"build-2803163510"},"reference-count":41,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Thompson Brain Mind Healthcare"},{"DOI":"10.13039\/501100000925","name":"national health and medical research council","doi-asserted-by":"publisher","award":["1193596"],"award-info":[{"award-number":["1193596"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Aust N Z J Psychiatry"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:p>Australia\u2019s reclassification of psilocybin as a Schedule 8 substance for treatment-resistant depression represents a significant shift in psychiatric policy. While this regulatory change positions Australia as a global leader in psychedelic medicine, its implementation has revealed substantial challenges. This article critically examines the regulatory, ethical and operational complexities surrounding the provision of psilocybin-assisted therapy in clinical practice. Key issues include limited prescriber access, absence of Australian Register of Therapeutic Goods-listed products, lack of standardised training pathways and significant cost barriers. Ethical considerations such as informed consent, cultural safety and therapeutic fidelity are also discussed, particularly in the context of trauma-informed care. This article proposes a series of structural recommendations to support safe and equitable deployment, including national training accreditation and fidelity monitoring tools. In addition, to maximise the efficacy of psilocybin-assisted therapy, we recommend that research explores the potential of neurobiologically informed stratification models to assist with treatment recommendations. These recommendations aim to enhance clinical integrity through evidence-based patient selection, improved safety, and to ensure that emerging psychedelic treatments are integrated responsibly within Australia\u2019s mental health system. By addressing these foundational gaps, Australia can move beyond regulatory novelty ensuring the therapeutic potential of these products is realised in a manner which is scientifically sound and upholds the integrity of psychiatric practice.<\/jats:p>","DOI":"10.1177\/00048674251398677","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T13:16:53Z","timestamp":1765977413000},"page":"115-122","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Psilocybin in the real world: Regulatory, ethical, and operational challenges in Australia\u2019s clinical landscape"],"prefix":"10.1177","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5209-2801","authenticated-orcid":false,"given":"Megan","family":"Dutton","sequence":"first","affiliation":[{"name":"Thompson Brain &amp; Mind Healthcare, Maroochydore, QLD, Australia"},{"name":"School of Medicine and Psychology, The Australian National University, Canberra, ACT, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Schwenn","sequence":"additional","affiliation":[{"name":"Thompson Brain &amp; Mind Healthcare, Maroochydore, QLD, Australia"},{"name":"School of Medicine and Psychology, The Australian National University, Canberra, ACT, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jules","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Thompson Brain &amp; Mind Healthcare, Maroochydore, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peta","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Thompson Brain &amp; Mind Healthcare, Maroochydore, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8483-1068","authenticated-orcid":false,"given":"Neil W","family":"Bailey","sequence":"additional","affiliation":[{"name":"School of Medicine and Psychology, The Australian National University, Canberra, ACT, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4217-8096","authenticated-orcid":false,"given":"Paul B","family":"Fitzgerald","sequence":"additional","affiliation":[{"name":"School of Medicine and Psychology, The Australian National University, Canberra, ACT, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Lagopoulos","sequence":"additional","affiliation":[{"name":"Thompson Brain &amp; Mind Healthcare, Maroochydore, QLD, Australia"},{"name":"School of Medicine and Psychology, The Australian National University, Canberra, ACT, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adem T","family":"Can","sequence":"additional","affiliation":[{"name":"Thompson Brain &amp; Mind Healthcare, Maroochydore, QLD, Australia"},{"name":"School of Medicine and Psychology, The Australian National University, Canberra, ACT, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2023.0549"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2021.10.863"},{"key":"e_1_3_3_4_1","unstructured":"Australian Health Practitioner Regulation Agency (2025) Medicinal Cannabis Prescribing. Available at: www.ahpra.gov.au\/Resources\/Medicinal-cannabis-prescribing.aspx (accessed 24 October 2025)."},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2022.866018"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11673-025-10454-3"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032994"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881118754710"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102799"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1101\/2025.05.28.25328532"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2012.00072"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102997"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206443"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.12.061"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01648-7"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1037\/pha0000684"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/00048674241240597"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/HRP.0000000000000179"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.0c00198"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20230884"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/00048674231174171"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/00048674221083868"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2025.119952"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-019-0574-2"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1556\/2054.2022.00232"},{"key":"e_1_3_3_26_1","doi-asserted-by":"crossref","unstructured":"Mihalopoulos C Langmead C Chatterton ML (2023 May 1) The trickey economics of subsidising psychedelics for mental health therapy. The Conversation. Available at: https:\/\/theconversation.com\/the-tricky-economics-of-subsidising-psychedelics-for-mental-health-therapy-201462 (accessed 28 August 2025).","DOI":"10.64628\/AA.xe9vtrh3a"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-023-01316-5"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.17398"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2017.08.035"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2021_266"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.14530"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-023-01404-6"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07624-5"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33578-1"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcbs.2019.11.002"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/medethics-2020-106070"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2024.03.016"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2023.1119115"},{"key":"e_1_3_3_39_1","unstructured":"Therapeutic Goods Administration (TGA) (2023) Notice of final decisions to amend (or not amend) the current Poisons Standard in relation to psilocybine and MDMA."},{"key":"e_1_3_3_40_1","unstructured":"Therapeutic Goods Administration (TGA) (2024) Therapeutic Goods (Standard for Psilocybine) Order 2024 (TGO 113)."},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s44220-024-00271-9"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.0c00194"}],"updated-by":[{"DOI":"10.1177\/00048674261450797","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000}}],"container-title":["Australian &amp; New Zealand Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00048674251398677","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00048674251398677","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00048674251398677","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:53:42Z","timestamp":1782734022000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00048674251398677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1177\/00048674251398677"],"URL":"https:\/\/doi.org\/10.1177\/00048674251398677","relation":{},"ISSN":["0004-8674","1440-1614"],"issn-type":[{"value":"0004-8674","type":"print"},{"value":"1440-1614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]}}}